These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 26623730)

  • 1. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
    Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G
    Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Kramer K; Modak S; Yataghene K; Cheung NK
    Oncoimmunology; 2015 Jul; 4(7):e1016704. PubMed ID: 26140243
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kushner BH; LaQuaglia MP; Modak S; Wolden SL; Basu EM; Roberts SS; Kramer K; Yataghene K; Cheung IY; Cheung NV
    Oncotarget; 2017 Nov; 8(56):95293-95302. PubMed ID: 29221128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.
    Cheung NK; Cheung IY; Kushner BH; Ostrovnaya I; Chamberlain E; Kramer K; Modak S
    J Clin Oncol; 2012 Sep; 30(26):3264-70. PubMed ID: 22869886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
    Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
    Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review.
    Żebrowska U; Balwierz W; Wechowski J; Wieczorek A
    Target Oncol; 2024 Mar; 19(2):143-159. PubMed ID: 38401028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies.
    Mora J; Castañeda A; Flores MA; Santa-María V; Garraus M; Gorostegui M; Simao M; Perez-Jaume S; Mañe S
    Front Pharmacol; 2020; 11():575009. PubMed ID: 33324208
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
    Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
    Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).
    Mora J; Cruz O; Lavarino C; Rios J; Vancells M; Parareda A; Salvador H; Suñol M; Carrasco R; Guillen A; Mañé S; de Torres C
    Clin Transl Oncol; 2015 Jul; 17(7):521-9. PubMed ID: 25596034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
    Peinemann F; van Dalen EC; Enk H; Tytgat GA
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
    Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidation Therapy for Newly Diagnosed Pediatric Patients with High-Risk Neuroblastoma Using Busulfan/Melphalan, Autologous Hematopoietic Cell Transplantation, Anti-GD2 Antibody, Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-2, and Haploidentical Natural Killer Cells.
    Talleur AC; Triplett BM; Federico S; Mamcarz E; Janssen W; Wu J; Shook D; Leung W; Furman WL
    Biol Blood Marrow Transplant; 2017 Nov; 23(11):1910-1917. PubMed ID: 28733263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.
    Cheung NK; Sowers R; Vickers AJ; Cheung IY; Kushner BH; Gorlick R
    J Clin Oncol; 2006 Jun; 24(18):2885-90. PubMed ID: 16682723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission.
    Mora J; Castañeda A; Gorostegui M; Santa-María V; Garraus M; Muñoz JP; Varo A; Perez-Jaume S; Mañe S
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29121. PubMed ID: 34022112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.